vs

Side-by-side financial comparison of i3 Verticals, Inc. (IIIV) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

i3 Verticals, Inc. is the larger business by last-quarter revenue ($52.7M vs $37.2M, roughly 1.4× Organogenesis Holdings Inc.). On growth, i3 Verticals, Inc. posted the faster year-over-year revenue change (-14.6% vs -57.1%). Over the past eight quarters, i3 Verticals, Inc.'s revenue compounded faster (-4.7% CAGR vs -46.5%).

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

IIIV vs ORGO — Head-to-Head

Bigger by revenue
IIIV
IIIV
1.4× larger
IIIV
$52.7M
$37.2M
ORGO
Growing faster (revenue YoY)
IIIV
IIIV
+42.4% gap
IIIV
-14.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
IIIV
IIIV
Annualised
IIIV
-4.7%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
IIIV
IIIV
ORGO
ORGO
Revenue
$52.7M
$37.2M
Net Profit
$484.0K
Gross Margin
30.8%
Operating Margin
3.1%
-185.1%
Net Margin
0.9%
Revenue YoY
-14.6%
-57.1%
Net Profit YoY
-76.5%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IIIV
IIIV
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$52.7M
$225.6M
Q3 25
$46.0M
$150.9M
Q2 25
$51.9M
$101.0M
Q1 25
$63.1M
$86.7M
Q4 24
$52.2M
$126.7M
Q3 24
$32.0M
$115.2M
Q2 24
$46.2M
$130.2M
Net Profit
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
$484.0K
$43.7M
Q3 25
$3.1M
$21.6M
Q2 25
$12.9M
$-9.4M
Q1 25
$-154.0K
$-18.8M
Q4 24
$2.1M
$7.7M
Q3 24
$117.9M
$12.3M
Q2 24
$-7.5M
$-17.0M
Gross Margin
IIIV
IIIV
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
IIIV
IIIV
ORGO
ORGO
Q1 26
-185.1%
Q4 25
3.1%
28.1%
Q3 25
3.2%
13.7%
Q2 25
-9.3%
-12.5%
Q1 25
8.0%
-30.9%
Q4 24
3.9%
8.1%
Q3 24
10.6%
5.4%
Q2 24
-2.8%
-10.7%
Net Margin
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
0.9%
19.4%
Q3 25
6.7%
14.3%
Q2 25
24.8%
-9.3%
Q1 25
-0.2%
-21.7%
Q4 24
3.9%
6.1%
Q3 24
368.2%
10.7%
Q2 24
-16.3%
-13.1%
EPS (diluted)
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
$0.02
$0.31
Q3 25
$0.14
$0.11
Q2 25
$0.50
$-0.10
Q1 25
$0.00
$-0.17
Q4 24
$0.08
$0.05
Q3 24
$4.93
$0.09
Q2 24
$-0.32
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IIIV
IIIV
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$37.5M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$358.5M
Total Assets
$595.9M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IIIV
IIIV
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$37.5M
$93.7M
Q3 25
$66.7M
$63.7M
Q2 25
$55.5M
$73.1M
Q1 25
$7.7M
$110.0M
Q4 24
$85.6M
$135.6M
Q3 24
$86.5M
$94.3M
Q2 24
$9.7M
$89.9M
Total Debt
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$12.0M
Q4 24
$26.2M
Q3 24
$26.2M
$62.3M
Q2 24
$374.1M
$63.8M
Stockholders' Equity
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
$358.5M
$300.1M
Q3 25
$389.6M
$255.1M
Q2 25
$383.3M
$233.2M
Q1 25
$385.2M
$242.9M
Q4 24
$375.0M
$262.9M
Q3 24
$379.7M
$278.5M
Q2 24
$249.7M
$263.5M
Total Assets
IIIV
IIIV
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$595.9M
$598.7M
Q3 25
$638.4M
$509.8M
Q2 25
$623.3M
$461.1M
Q1 25
$646.4M
$467.4M
Q4 24
$726.2M
$497.9M
Q3 24
$730.7M
$446.3M
Q2 24
$861.7M
$443.2M
Debt / Equity
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.03×
Q4 24
0.07×
Q3 24
0.07×
0.22×
Q2 24
1.50×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IIIV
IIIV
ORGO
ORGO
Operating Cash FlowLast quarter
$14.1M
Free Cash FlowOCF − Capex
$13.8M
FCF MarginFCF / Revenue
26.2%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
29.18×
TTM Free Cash FlowTrailing 4 quarters
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
$14.1M
$39.4M
Q3 25
$14.0M
$3.1M
Q2 25
$7.4M
$-32.9M
Q1 25
$-27.1M
$-19.9M
Q4 24
$11.5M
$10.9M
Q3 24
$15.1M
$8.7M
Q2 24
$8.1M
$4.7M
Free Cash Flow
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
$13.8M
$34.8M
Q3 25
$13.5M
$844.0K
Q2 25
$6.8M
$-36.5M
Q1 25
$-27.6M
$-23.6M
Q4 24
$11.0M
$7.6M
Q3 24
$14.6M
$6.1M
Q2 24
$7.2M
$2.9M
FCF Margin
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
26.2%
15.4%
Q3 25
29.5%
0.6%
Q2 25
13.1%
-36.1%
Q1 25
-43.8%
-27.2%
Q4 24
21.1%
6.0%
Q3 24
45.6%
5.3%
Q2 24
15.6%
2.2%
Capex Intensity
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
0.6%
2.1%
Q3 25
0.9%
1.5%
Q2 25
1.0%
3.6%
Q1 25
0.8%
4.2%
Q4 24
0.9%
2.7%
Q3 24
1.7%
2.2%
Q2 24
1.9%
1.4%
Cash Conversion
IIIV
IIIV
ORGO
ORGO
Q1 26
Q4 25
29.18×
0.90×
Q3 25
4.52×
0.14×
Q2 25
0.57×
Q1 25
Q4 24
5.59×
1.43×
Q3 24
0.13×
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons